Reforgene approved as a postdoctoral research workstation sub-station
Recently, Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene") received a notice from the Office of the National Postdoctoral Management Committee approving the establishment of a postdoctoral research workstation sub-station. This achievement marks a new breakthrough for Reforgene in attracting and cultivating high-level talent and in industry-research integration, injecting strong talent momentum into the company's continuous development of globally competitive innovative gene editing medicines.
Reforgene is a leading technology innovation enterprise in China's biomedical field, focused on the R&D and translational application of gene editing technology, deeply cultivating innovation in curative medicines for major diseases, continuously advancing core technology breakthroughs, building international competitiveness in the gene editing technology field, and forming a complete R&D system and professional technical team covering "early discovery, preclinical development and clinical trials". The approval of this postdoctoral research workstation fully reflects the company's comprehensive strength in gene editing technology and product accumulation, full-chain R&D system construction, and high-level talent echelon building.
In terms of research platforms and talent development, Reforgene has gradually built a high-level R&D team exploring gene editing for the treatment of major diseases, and has successively undertaken major research projects such as the Guangdong Provincial Key R&D Program and the National Key R&D Program. Relying on the postdoctoral research workstation sub-station as a high-level innovation platform, Reforgene will further deepen industry-academia-research-medicine collaboration, focus on key technologies, and build a top talent echelon through the combined approach of attraction and cultivation. The company will continue to enhance its core competitiveness, accelerate the R&D and implementation of innovative gene editing medicines, contribute more innovative achievements to the high-quality development of the biomedical industry, illuminate more patients' paths to new life, and strive to grow into a leading gene editing technology enterprise with international influence.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.